BTK and B-cell chronic lymphocytic leukemia: Zanubrutinib is a highly potent and selective covalent BTK inhibitor approved for the treatment of mantle cell lymphoma, marginal zone lymphoma, CLL/small lymphocytic lymphoma, and WM (23).